According to researchers at the University of Maryland School of Medicine, aspirin use reduced the risk of death in hospitalized COVID-19 patients. The researchers found that patients who were receiving aspirin were less likely to be placed in the ICU or on a mechanical ventilator. These patients were more likely to survive COVID-19 than those who were not taking aspirin. The researchers conducted their study on the medical records of 412 COVID-19 patients who had an average age of 55 years and who were hospitalized due to the complication of COVID-19. About a quarter of patients were receiving low-dose aspirin (usually 81mg) before they were admitted or following admission to manage their cardiovascular disease.
The study revealed that aspirin use was associated with a 47% decrease in the risk of mortality, a 43% decrease in the risk of ICU admission, and a 44% reduction in the risk of being put on a mechanical ventilator. The aspirin group also did not experience any significant increase in adverse events such as major bleeding. COVID-19 increases the risk of blood clots in the visceral organs and blood vessels. The researchers believe that the blood-thinning effects of the aspirin prevent micro clot formation. Further clinical trials are necessary to prove the results. If aspirin shows this effect on COVID-19, it would make aspirin the first widely available, OTC medication that reduces COVID-19-related mortality.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here